Share on LinkedInShare on LinkedIn

ARTICLE · 19 MARCH 2025

Insulet Corp. May Have To Choose Between $452 Million Jury Award Or Permanently Blocking Competitor From Utilizing Its Trade Secrets

Benesch, Friedlander, Coplan & Aronoff LLP
Benesch, Friedlander, Coplan & Aronoff LLP
Contributor
Explore more from Benesch, Friedlander, Coplan & Aronoff LLP

After receiving a jury verdict awarding $452 million in damages against a rival company for misappropriation of trade secrets, the prevailing party, Insulet Corp.

United StatesIntellectual Property

After receiving a jury verdict awarding $452 million in damages against a rival company for misappropriation of trade secrets, the prevailing party, Insulet Corp., may have to choose between portions of the damages award or permanently blocking the rival company from continuing to sell its products based on the stolen technology.

In August 2023, Insulet, a medical device company, sued a rival company, EOFlow, for misappropriation of Insulet's trade secrets. On December 3, 2024, after a four-week trial in the District of Massachusetts, the jury returned a verdict in favor of Insulet finding that EOFlow misappropriated four of Insulet's trade secrets in creating its insulin patch pump. The jury awarded Insulet $170 million in compensatory damages and $282 million in exemplary or punitive damages, totaling $452 million.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from